Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL

PHASE2/PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2006

Primary Completion Date

January 31, 2007

Conditions
Chronic Myeloid LeukemiaAcute Lymphoblastic Leukemia
Interventions
DRUG

Dasatinib

Trial Locations (20)

Unknown

Local Institution, Budapest

Local Institution, Bologna

Local Institution, Orbassano (To)

Local Institution, Roma

Local Institution, Nijmegen

Local Institution, Rotterdam

Local Institution, Gdansk

Local Institution, Katowice

Local Institution, Krakow

Local Instiution, Lodz

Local Institution, Lublin

Local Institution, Warsaw

Local Institution, Moscow

Local Institution, Saint Petersburg

Local Institution, Cambridge

Local Institution, Glasgow

Local Institution, London

Local Institution, Liverpool

Local Institution, Newcastle

Local Institution, Birmingham

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00349518 - Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL | Biotech Hunter | Biotech Hunter